Institution and location: Sheffield University Medical School Degree: MB CHB Year(s): 1978 Field of study: Medicine
Institution and location: Sheffield University Medical School Degree: MD Year(s): 1982 Field of study: Cancer medicine
Professional Experience
1978–1982 General medicine, Royal London Hospital
1982–1989 Dermatology St Thomas’s Hospital, London
1989–1995 Senior lecturer dermatology, Royal London Hospital
1995–present Professor of dermatology and Cancer Research UK senior clinical scientist, genetic epidemiology lab and cancer medicine research group, St James’s University Hospital, Leeds, UK
Publications
Gruhlich A, Bataille V, Newton Bishop JA, McCarthy W, Swerdlow A, Cuzick J. Naevi and pigmentary characteristics as risk factors for melanoma in a high-risk population: a case-control study in New South Wales, Australia. Internatioanl Journal of Cancer,67:485-491, 1996
Harland M, Meloni R, Gruis N, Pinney E, Brookes S, Spurr N, Frischauf A-M, Bataille V, Peters G, Cuzick J, Selby P, Bishop DT, Newton Bishop JA. Germline mutations of the CDKN2 gene in UK melanoma families. Human Molecular Genetics, 6:2061-2067, 1997.
Bataille V, Gruhlich A, Sasieni P, Swerdlow A, Newton Bishop JA, McCarthy W, Hersey P, Cuzick J. The association between naevi and melanoma in populations with different levels of sun exposure: a joint case-control study of melanoma in the UK and in Australia. British Journal of Cancer 77:505-510, 1998
Pollock PM, Spurr N, Bishop T, Newton Bishop JA, Gruis N, van der Velden PA, Goldstein AM, Tucker MA, Foulkes WD, Barnhill R, Haber D, Fountain J, Hayward NK. Haplotype analysis of 2 recurrent CDKN2A mutations in 10 melanoma families: evidence for common founders and independent mutations. Human Mutation 11:424-431, 1998
Wachsmuth Rachel C, Harland Mark, Newton Bishop Julia A. The atypical mole syndrome and predisposition to melanoma. New England Journal of Medicine 339:348-349, 1998
Bataille V, Sasieni P, Gruhlich A, Swerdlow A, McCarthy W, Hersey P, Newton Bishop JA, Cuzick J. Solar keratoses: a risk factor for melanoma but negative association with melanocytic naevi. International Journal of Cancer, 78:8-12, 1998
Newton Bishop JA, Harland M, Bishop DT. The genetics of melanoma: the UK experience. Clinical and Experimental Dermatology, 23:158-161, 1998
Newton Bishop JA, Harland M, Bennett DC, Bataille V, Goldstein AM, Tucker MA, Ponder BAJ, Cuzick J, Selby P, Bishop DT. Mutation testing in melanoma families: INK4A, CDK4 and INK4D. British Journal of Cancer, 80:295-300, 1999.
Kupsch JM, Tidman NH, Kang NV, Truman H, Hamilton S, Patel N, Newton Bishop JA, Leigh IM, Crowe JS. Isolation of human tumor-specific antibodies by selection of an antibody phage library on melanoma cells. Clinical Cancer Research, 5(4): 925-31,1999
Harland M, Holland EA, Ghiorzo P, Mantelli M, Bianchi-Scarra G, Goldstein AM, Tucker MA, Ponder BAJ, Mann G, Bishop DT, Newton Bishop JA. Mutation screening of the CDKN2A promotor in melanoma families. Genes, Chromosomes and Cancer, 28:45-57,2000
Newton Bishop JA, Bradburn M, Bergman W, Osterlind A, Pinney E, Rosdahl I, Scerri L, Weichenthal M, Mant D, Breitbart EW, Karlssons P, Altman D. Teaching non-specialist health care professionals how to identify the atypical mole syndrome phenotype: a multinational study. British Journal of Dermatology,142:331-337,2000
Newton Bishop JA, Wachsmuth RC, Harland M, Bataille V, Pinney E, Mack P, Baglietto L, Cuzick J, Bishop DT. Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations. Journal of Investigative Dermatology 114:28-33,2000
Newton Bishop JA, Wachsmuth RC, Harland M, Bataille V, Pinney E, Mack P, Baglietto L, Cuzick J, Bishop DT. Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations. Journal of Investigative Dermatology 114:28-33,2000
Randerson-Moor JA, Harland M, Williams S, Cuthbert-Heavens D, Sheridan E, Aveyard J, Sibley K, Whitaker L, Knowles M, Newton Bishop JA, Bishop DT. A germline deletion of p14ARF but not CDKN2A in a melanoma-neural system tumour syndrome family. Human Molecular Genetics, 10:55-62, 2001
Wachsmuth RC, Gaut RM, Barrett JH, Saunders C, Randerson-Moor JA, Eldridge A, Martin N, Bishop T, Newton-Bishop JA. Heritability and gene-environment interactions for melanocytic nevus density examined in a UK adolescent twin study. Journal of Investigative Dermatology,117: 348-52,2001.
Mark Harland, Sushila Mistry, D Timothy Bishop and Julia A Newton Bishop. A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees. Human Molecular Genetics,10: 2679-2686,2001
Lens, MB, Dawes M, Goodacre T, Newton Bishop JA. Elective lymph node dissection in melanoma patients: systematic review and meta-analysis of randomised controlled trials. Archives of Surgery, 137:458-461,2002
Chandra G. Bertram, Rupert M. Gaut, Jennifer H. Barrett, Elizabeth Pinney, Linda Whitaker, Faye Turner, Veronique Bataille, Isabel dos Santos Silva, Anthony J.Swerdlow, D Timothy. Bishop, Julia A. Newton Bishop. An assessment of the CDKN2A variant ala148thr as a nevus / melanoma susceptibility allele. Journal of Investigative Dermatology 2002,119: 961-965
D. Timothy Bishop, Florence Demenais, Alisa M. Goldstein, Wilma Bergman, Julia Newton Bishop, et al and The Melanoma Genetics Consortium. Geographical Variation in the Penetrance of CDKN2A Mutations for Melanoma. Journal National Cancer Institute, 94:894-903, 2002
Marko B Lens, Martin Dawes, Julia Newton-Bishop, Tim Goodacre. Tumour thickness is a predictor of occult metastasis in melanoma patients, stage I and II, undergoing sentinel lymph node biopsy: an evidence based analysis of published data. British Journal Of Surgery, 89(10):1223-27,2002
Lens, M. B., Dawes, M, Goodacre, T., Newton- Bishop, J. A. Excision margins in the treatment of primary cutaneous melanoma: a systematic review of randomized controlled trials comparing narrow vs wide excision. Archives of Surgery 2002,137:1101-5
Thomas J Huot, Janice Rowe, Mark Harland, Sarah Drayton, Sharon Brookes, Chandra Gooptu, Patricia Purkis, Veronique Bataille, Eiji Hara, Julia Newton-Bishop and Gordon Peters. Biallelic mutations in p16INK4a confer resistance to Ras and Ets induced senescence in human diploid fibroblasts. Molecular and Cellular Biology,2002,22:8135-43
Stefoski J, Johnston C, Adamson P, Wright A, Newton-Bishop JA, Batman P, Neal RD, Forman D. How complete has skin cancer registration been in the UK? A Study from Yorkshire. European Journal of Cancer Prevention, 2003, 12:125-33
Elizabeth Gillanders, Suh-Hang Hank Juo, Elizabeth A. Holland, MaryPat Jones, Derek Nancarrow, Diana Freas-Lutz, Raman Sood, Mezbah Faruque, Carol Markey, Rick Kefford, Jane Palmer, Wilma Bergman, D. Timothy Bishop, Margaret A. Tucker, Brigitte Bressac-de Paillerets, Johan Hansson, Mitchell Stark, Nelleke Gruis, Julia Newton Bishop, Alisa M. Goldstein, Joan E. Bailey-Wilson, Graham J. Mann, Nicholas Hayward, Jeffrey Trent and The Melanoma Genetics Consortium. Localization of a novel melanoma susceptibility locus to 1p22. American Journal of Human Genetics August 2003
Thomas, J. M. Newton-Bishop, JA et al. Excision margins in high-risk malignant melanoma. N Engl J Med 350, 757-66 (2004).
Bataille, V., Winnett, A., Sasieni, P., Newton Bishop, J. A. & Cuzick, J. Exposure to the sun and sunbeds and the risk of cutaneous melanoma in the UK: a case-control study. Eur J Cancer 40, 429-35 (2004).
